Literature DB >> 1867956

Clinical pharmacology through the looking glass: reflections on the racemate vs enantiomer debate.

M S Lennard1.   

Abstract

Mesh：

Year:  1991        PMID： 1867956      PMCID： PMC1368570          DOI： 10.1111/j.1365-2125.1991.tb05583.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  21 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns; E W Wuis; E J Veringa
Journal:  Biochem Pharmacol       Date:  1988-01-01       Impact factor: 5.858

3.  Bias in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns; E W Wuis
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

4.  Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview.

Authors:  D E Drayer
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

Review 5.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 6.  Problems in therapeutic drug monitoring: the dilemma of enantiomeric drugs in man.

Authors:  D E Drayer
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

7.  Ocular beta-blockers and systemic effects.

Authors:  F T Fraunfelder
Journal:  Arch Intern Med       Date:  1986-06

8.  Bronchial beta-adrenoceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects.

Authors:  R Richards; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

9.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Stereospecificity of the enzymatic biotransformation of the enantiomers of prilocaine (Citanest).

Authors:  B Akerman; S Ross
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1970
View more
  7 in total

Review 1.  Chirality and nonsteroidal anti-inflammatory drugs.

Authors:  P J Hayball
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Chirality in new drug development. Clinical pharmacokinetic considerations.

Authors:  R L Nation
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

3.  Thalidomide-induced neuropathy and genetic differences in drug metabolism.

Authors:  C C Harland; G B Steventon; J R Marsden
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Studies of metabolite-protein interactions: a review.

Authors:  Ryan Matsuda; Cong Bi; Jeanethe Anguizola; Matthew Sobansky; Elliott Rodriguez; John Vargas Badilla; Xiwei Zheng; Benjamin Hage; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-11-25       Impact factor: 3.205

5.  Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.

Authors:  T Walley; Y Tsao; A Scott; E Mackay; M Vandenburg; A Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

Review 6.  Stereoisomers and drug toxicity. The value of single stereoisomer therapy.

Authors:  A K Scott
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

7.  Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro.

Authors:  M Villanueva; R Heckenberger; H Strobach; M Palmér; K Schrör
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.